<DOC>
	<DOCNO>NCT00832572</DOCNO>
	<brief_summary>This study determine whether ranolazine effective treatment neuropathic pain patient coronary artery disease . Eligibility required neurological examination study doctor assessment patient 's pain . Eligible participant randomize receive blind study medication total 12 week .</brief_summary>
	<brief_title>Study Ranexa Patients With Coronary Artery Disease Painful Polyneuropathy</brief_title>
	<detailed_description />
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Ranolazine</mesh_term>
	<criteria>Males female age â‰¥ 18 year Coronary artery disease clinically diagnose peripheral neuropathy Willing able provide sign informed consent Health Insurance Portability Accountability Act ( HIPAA ) authorization Willing able comply requirement protocol follow direction clinic staff History allergy intolerance ranolazine Any condition concomitant medication would preclude safe use ranolazine outline prescribe information sheet ( see Appendix E ) In judgment investigator , clinicallysignificant ongoing medical condition might jeopardize patient 's safety interfere absorption , distribution , metabolism excretion study drug In judgment investigator , clinicallysignificant abnormal physical finding screen ( exclude patient 's peripheral neuropathy condition ) Use experimental investigational drug device within 30 day prior screen Pregnant breast feeding , ( premenopausal ) , practice acceptable method birth control ( detailed Inclusion Criterion 4 ) Had receive prior treatment , investigational exposure , ranolazine within 7 day prior randomization Clinically significant hepatic impairment Had endstage renal disease require dialysis Psychological addictive disorder ( limited , include drug and/or alcohol dependency ) may preclude patient consent compliance , may confound study interpretation Positive pregnancy test Baseline ( prerandomization , Day 0 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Coronary Artery Disease</keyword>
	<keyword>Pain</keyword>
	<keyword>Peripheral Neuropathy</keyword>
	<keyword>Polyneuropathy</keyword>
</DOC>